-
Puma Biotechnology (PBYI) PT Raised to $29 at RBC Capital
-
Puma Biotechnology (PBYI) PT Slashed 50% to $26 at RBC Capital
-
Pre-Open Movers 01/03: (DRRX) (VSAR) (GPS) Higher; (OPK) (AOBC) (MCD) Lower (more...)
-
Puma Biotechnology (PBYI) PT Raised to $88 at RBC Capital
-
Pre-Open Movers 01/27: (LOXO) (DVAX) (FOR) Higher; (INSY) (HLF) (PRGO) Lower (more...)
-
Puma Biotechnology (PBYI) PT Lowered to $48 at RBC Capital Following Another Regulatory Path/Strategy Change
-
Puma Biotechnology to Present at RBC Capital Markets Healthcare Conference
-
Puma Biotechnology (PBYI) Abstract Data Helps Explain Need to Change Trial - RBC
-
NDA Acceptance Removes Overhang on Puma Biotechnology (PBYI) - RBC
-
Puma Biotechnology (PBYI) PT Raised to $46 at RBC Capital After Neratinib NDA Filed
-
UPDATE: RBC Capital Cuts Puma Biotechnology (PBYI) to Sector Perform Following Delayed Neratinib NDA
-
Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference
-
Notes from Puma Biotechnology (PBYI) Preliminary Phase II Conference Call - RBC
-
RBC Capital Starts Puma Biotechnology (PBYI) at Outperform
-
Pre-Open Stock Movers 06/02: (NPSP) (PL) (BRCM) Higher; (PBYI) (MTZ) (CYTK) Lower (more...)